ENDRA Life Sciences Inc. 10-Q

Item 5. Other Information None of the Company’s directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended September 30, 2024. 25 Table of Contents Item 6. Exhibits Exhibit Number Description 3.1 Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on May 12, 2017) 3.2 Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 18, 2020) 3.3 Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 9, 2024) 3.4 Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on November 5, 2024) 3.5 Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form S-1 (File No. 333-214724), as amended, originally filed on November 21, 2016) 4.1 Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1 filed on May 10, 2024) 4.2 Form of Series A Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1 filed on May 31, 2024) 4.3 Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1 filed on May 31, 2024) 4.4 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.4 to the Company’s Registration Statement on Form S-1 filed on May 10, 2024) 4.5 Form of Amendment to Series A Warrant (incorporated by reference to Exhibit 3.8 to the Company’s Form 10-Q filed on August 14, 2024) 4.6 Form of Amendment to Series B Warrant (incorporated by reference to Exhibit 3.9 to the Company’s Form 10-Q filed on August 14, 2024) 10.1†* Employment Agreement, dated August 13, 2024, by and between the Company and Alexander Tokman 31.1† Certification of Periodic Report by Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) 31.2† Certification of Periodic Report by Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) 32.1† Certification of Periodic Report by Chief Executive Officer and Principal Financial Officer pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) 101.INS# XBRL Instance Document 101.SCH# XBRL Taxonomy Schema 101.CAL# XBRL Taxonomy Extension Calculation Linkbase 101.DEF# XBRL Taxonomy Extension Definition Linkbase 101.LAB# XBRL Taxonomy Extension Label Linkbase 101.PRE# XBRL Taxonomy Extension Presentation Linkbase * Indicates management compensatory plan, contract or arrangement. † Filed or furnished herewith. # To be filed by amendment. 26 Table of Contents SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ENDRA LIFE SCIENCES INC. Date: November 19, 2024 By: /s/ Alexander Tokman Alexander Tokman Chief Executive Officer and Chairman (Principal Executive Officer) ENDRA LIFE SCIENCES INC. Date: November 19, 2024 By: /s/ Richard Jacroux Richard Jacroux Chief Financial Officer (Principal Financial and Accounting Officer) 27